Granite Bio Emerges with $100M Funding and Novel Immunology Pipeline for IBD and Allergies
• Versant Ventures has launched Granite Bio with $100 million in funding, advancing two novel antibody drugs targeting inflammatory conditions through its Ridgeline Therapeutics initiative.
• Granite's lead candidate GRT-001 targets pro-inflammatory monocytes in IBD and is currently in Phase 1 trials, with ulcerative colitis studies planned for later this year.
• The company's second candidate, GRT-002, targets IL-3 for treating itch and allergies, representing a different approach from established therapies like Dupixent and Cosentyx.
Bioxodes Advances BIOX-101 for Intracerebral Hemorrhage Treatment with New Funding and Clinical Milestones
• Bioxodes secured €2.7 million in Series A extension funding to advance BIOX-101, a novel therapy for intracerebral hemorrhage (ICH).
• The funding supports the completion of the BIRCH Phase 2a trial and preparations for a Phase 2b trial of BIOX-101 in ICH.
• Interim data from the BIRCH Phase 2a trial, evaluating BIOX-101 in ICH patients, is expected in Q1 2025.
• BIOX-101, derived from tick saliva, aims to reduce secondary brain injuries post-hemorrhagic stroke by preventing clot formation and neuroinflammation.
© Copyright 2025. All Rights Reserved by MedPath